

**Attachment A -- Opportunity to Submit Scientific Information E-mail**

**From:** Agency for Healthcare Research and Quality (AHRQ) <updates@subscriptions.ahrq.gov>

**Sent:** Thursday, March 10, 2022 5:23 PM

**To:** Bennis, Jenae (AHRQ/CEPI) <Jenae.Bennis@ahrq.hhs.gov>

**Subject:** EHC Program Update: Protocol on Postpartum Management of Women who Experience Hypertensive Disorders of Pregnancy Now Available



Agency for Healthcare  
Research and Quality

www.ahrq.gov

**Effective Health Care**

## **Opportunity to Submit Scientific Information**

The Effective Health Care (EHC) Program is interested in receiving supplemental evidence and data (SEADs) for systematic reviews that are relevant to the questions in our evidence reports. To ensure that it has full access to relevant research, whether or not it is published, the EHC Program is interested in receiving SEADs containing detailed study-specific information. Opportunities to submit scientific information are available for:

[Postpartum Home Blood Pressure Monitoring, Postpartum Treatment of Hypertensive Disorders of Pregnancy, and Peripartum Magnesium Sulfate Regimens for Preeclampsia With Severe Features](#)

(Available for submission until April 1, 2022)

The purpose of the review is to summarize the findings from (1) studies of home BP monitoring in the postpartum period, (2) studies of pharmacological treatment of HDP in the postpartum period, and (3) studies comparing the effectiveness and harms of different MgSO<sub>4</sub> regimens in patients with preeclampsia with severe features to prevent eclampsia during the peripartum period. For the third topic, the peripartum period is operationally defined as the time interval prior to, during, or after delivery when individuals may be diagnosed with preeclampsia with severe features. For all topics, the review will summarize findings related to differences in treatment effectiveness (and harms) in different populations, with an emphasis, as feasible, on factors related to healthcare disparities and pregnancy-related risk factors.

*(Section 944 (c) of the Public Health Service Act [42 U.S.C. 299c 3(c)] requires that information collected for research conducted or supported by AHRQ that identifies individuals or establishments be used only for the purpose for which it was supplied unless they consent to the use of the information for another purpose.)*

*About us: AHRQ's Effective Health Care Program is committed to providing the best available evidence on the outcomes, benefits and harms, and appropriateness of drugs, devices, and health care services and by helping health care professionals, patients, policymakers, and health care systems make informed health care decisions. The program partners with research centers, academic institutions, health professional societies, consumer organizations, and other stakeholders to conduct research, evidence synthesis, evidence translation, dissemination, and implementation of research findings.*

To learn more: <https://effectivehealthcare.ahrq.gov/>

Contact us at [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov)